Organovo Holdings Inc (ONVO) Stake Raised by Vanguard Group Inc

Vanguard Group Inc grew its position in Organovo Holdings Inc (NASDAQ:ONVO) by 1.1% during the 3rd quarter, according to the company in its most …

Organovo logoVanguard Group Inc grew its position in Organovo Holdings Inc (NASDAQ:ONVO) by 1.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,771,558 shares of the medical research company’s stock after acquiring an additional 52,073 shares during the quarter. Vanguard Group Inc owned about 4.12% of Organovo worth $5,487,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Virtu Financial LLC purchased a new stake in shares of Organovo in the third quarter valued at $138,000. Renaissance Technologies LLC raised its stake in shares of Organovo by 179.2% in the second quarter. Renaissance Technologies LLC now owns 1,244,600 shares of the medical research company’s stock valued at $1,742,000 after acquiring an additional 798,800 shares during the period. Vanguard Group Inc. raised its stake in shares of Organovo by 1.1% in the third quarter. Vanguard Group Inc. now owns 4,771,558 shares of the medical research company’s stock valued at $5,487,000 after acquiring an additional 52,073 shares during the period. BlackRock Inc. raised its stake in shares of Organovo by 14.8% in the second quarter. BlackRock Inc. now owns 6,966,411 shares of the medical research company’s stock valued at $9,753,000 after acquiring an additional 897,113 shares during the period. Finally, ARK Investment Management LLC raised its stake in shares of Organovo by 20.8% in the third quarter. ARK Investment Management LLC now owns 17,951,107 shares of the medical research company’s stock valued at $20,644,000 after acquiring an additional 3,090,669 shares during the period. 36.22% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ ONVO traded up $0.01 during mid-day trading on Tuesday, reaching $1.01. The company had a trading volume of 11,445 shares, compared to its average volume of 560,614. The stock has a market cap of $119.49 million, a PE ratio of -3.16 and a beta of 1.84. Organovo Holdings Inc has a 52 week low of $0.90 and a 52 week high of $2.09.

Organovo (NASDAQ:ONVO) last posted its quarterly earnings results on Thursday, February 7th. The medical research company reported ($0.06) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.07) by $0.01. The firm had revenue of $0.78 million for the quarter, compared to analysts’ expectations of $0.87 million. Organovo had a negative net margin of 770.79% and a negative return on equity of 67.55%. Research analysts forecast that Organovo Holdings Inc will post -0.25 earnings per share for the current year.

Several equities research analysts have recently weighed in on ONVO shares. Zacks Investment Research downgraded shares of Organovo from a “buy” rating to a “hold” rating in a research note on Tuesday, February 5th. HC Wainwright initiated coverage on shares of Organovo in a report on Thursday, December 13th. They issued a “buy” rating and a $2.50 price target on the stock.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Fairfield Current and is the property of of Fairfield Current. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.fairfieldcurrent.com/news/2019/02/12/organovo-holdings-inc-onvo-stake-raised-by-vanguard-group-inc.html.

Organovo Company Profile

Organovo Holdings, Inc, a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.

Featured Article: Intrinsic Value

Want to see what other hedge funds are holding ONVO?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organovo Holdings Inc (NASDAQ:ONVO).

Institutional Ownership by Quarter for Organovo (NASDAQ:ONVO)

Receive News & Ratings for Organovo Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Organovo and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Renaissance Technologies LLC Boosts Holdings in Organovo Holdings Inc (NASDAQ:ONVO)

Renaissance Technologies LLC lifted its position in shares of Organovo Holdings Inc (NASDAQ:ONVO) by 25.4% during the third quarter, according to …

Organovo logoRenaissance Technologies LLC lifted its position in shares of Organovo Holdings Inc (NASDAQ:ONVO) by 25.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,561,000 shares of the medical research company’s stock after purchasing an additional 316,400 shares during the quarter. Renaissance Technologies LLC owned 1.35% of Organovo worth $1,795,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of ONVO. ARK Investment Management LLC lifted its holdings in Organovo by 20.8% in the 3rd quarter. ARK Investment Management LLC now owns 17,951,107 shares of the medical research company’s stock valued at $20,644,000 after purchasing an additional 3,090,669 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Organovo by 1.5% during the 3rd quarter. BlackRock Inc. now owns 7,068,897 shares of the medical research company’s stock worth $8,129,000 after acquiring an additional 102,486 shares during the period. Finally, Virtu Financial LLC purchased a new position in shares of Organovo during the 3rd quarter worth $138,000. 36.22% of the stock is currently owned by institutional investors and hedge funds.

Several research analysts have recently commented on ONVO shares. Zacks Investment Research lowered Organovo from a “buy” rating to a “hold” rating in a report on Tuesday, February 5th. HC Wainwright started coverage on Organovo in a report on Thursday, December 13th. They set a “buy” rating and a $2.50 price target on the stock.

NASDAQ ONVO opened at $1.00 on Tuesday. The stock has a market capitalization of $119.49 million, a price-to-earnings ratio of -3.13 and a beta of 1.84. Organovo Holdings Inc has a 1-year low of $0.90 and a 1-year high of $2.09.

Organovo (NASDAQ:ONVO) last released its earnings results on Thursday, February 7th. The medical research company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01. The company had revenue of $0.78 million during the quarter, compared to the consensus estimate of $0.87 million. Organovo had a negative return on equity of 67.55% and a negative net margin of 770.79%. Equities research analysts anticipate that Organovo Holdings Inc will post -0.25 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Renaissance Technologies LLC Boosts Holdings in Organovo Holdings Inc (NASDAQ:ONVO)” was originally published by Fairfield Current and is owned by of Fairfield Current. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.fairfieldcurrent.com/news/2019/02/12/renaissance-technologies-llc-boosts-stake-in-organovo-holdings-inc-onvo.html.

Organovo Profile

Organovo Holdings, Inc, a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.

Featured Article: How to Use the New Google Finance Tool

Institutional Ownership by Quarter for Organovo (NASDAQ:ONVO)

Receive News & Ratings for Organovo Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Organovo and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Global 3D Bioprinting Market | Industry Size, Analysis 2012-2017, Future Scope 2018-2023

3D Systems Corp., Aspect Biosystems Ltd, GeSIM GmbH,Bio3D Technologies,BioBots, Inc.,Cyfuse Biomedical KK,Envision TEC GmbH,Organovo …

3D Bioprinting

Global 3D Bioprinting Market “Research Report 2018-2023 This report researches the worldwide 3D Bioprinting Market size (value, capacity, production and consumption) in key regions like North America, Europe, Asia Pacific (China, Japan) and other regions. The report provides a unique tool for evaluating the Market, highlighting opportunities, and supporting strategies. This report recognizes that in this rapidly-evolving and competitive environment, up-to-date Marketing information is essential to monitor performance and make critical decisions for growth and profitability. It provides information on trends and developments, and focuses on Markets and materials, capacities and technologies, and on the changing dynamics of the 3D Bioprinting Market.

Request a Sample of 3D Bioprinting Market Report from: https://www.marketreportsworld.com/enquiry/request-sample/12343660

3D Bioprinting Market coopetition by top makers/players, with 3D Bioprinting deals volume, Price (USD/Unit), income (Million USD) and piece of the overall industry for every producer/player; the best Information including:

3D Systems Corp., Aspect Biosystems Ltd, GeSIM GmbH,Bio3D Technologies,BioBots, Inc.,Cyfuse Biomedical KK,Envision TEC GmbH,Organovo Holdings Inc,Rainbow Biosciences LLC,RegenHU SA,Stratasys Ltd,TeVido Biodevices, Inc.,3D Bioprinting Solutions

The 3D Bioprinting Market 2018-2025 report offers an extensive and precise estimates and forecasts study of 3D Bioprinting industry along with the analysis of essential features providing key industry insights to the readers. The 3D Bioprinting Market research report further delivers a methodical outlook of the industry by studying key components impacting the industry such as 3D Bioprinting market growth, consumption volume, emerging trends and industry cost structures during the forecast period.

Global 3D Bioprinting market report consist data that can be essential when it comes to conquering the market or making a mark in the market as an upcoming player in the segment. The 3D Bioprinting market report is an analysed assessment of the prime challenges, opportunities and risks that are to come in the market in the terms of sales, revenue, cost, import/export. The 3D Bioprinting market research report is a resourceful report which provides current as well as upcoming technical and financial challenges and opportunities of the industry from 2018-2025. The report proves essential when it comes to market classification, definition and applications.

Have Any Query? Ask Our Expert at: https://www.marketreportsworld.com/enquiry/pre-order-enquiry/12343660

The tremendous statistical surveying information incorporated into the analysis is the aftereffect of broad essential and auxiliary research exercises. Overviews, individual meetings, and contributions from industry specialists frame the essence of essential research exercises and information gathered from exchange diaries, industry databases, and legitimate paid sources shape the premise of optional research. The report additionally incorporates a point by point subjective and quantitative examination of the market, with the assistance of data gathered from market members working crosswise over key segments of the market esteem chain. A different analysis of full scale and miniaturized scale financial viewpoints, directions, and patterns impacting the general improvement of the market is additionally incorporated into the report.

The statistical surveying gives an expert and top to bottom examination on the present condition of the territorial and Global, concentrating on the limit and generation volumes, Producers, costs, import and fare, Market estimate and buyers, including the impartial verifiable information and long haul figures. This report gives point by point examination of overall markets for Global 3D Bioprinting Market Research Report 2018 and gives broad market figures 2018-2025 by area/nation and subsectors.

This report gives inside and out analysis of the 3D Bioprinting Market and gives Market measure (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the gauge time frame: 2018 – 2025, thinking about 2016 as the base year. It clarifies potential income opportunity crosswise over various fragments and clarifies appealing speculation recommendation grid for this market. This analysis likewise gives key bits of knowledge about market drivers, restrictions, openings, new item dispatches, endorsements, provincial viewpoint, and focused methodologies embraced by the main players. It profiles driving players in the Global 3D Bioprinting Market dependent on the accompanying parameters organization review, budgetary execution, item portfolio, geological nearness, dissemination systems, key improvements and procedures and feasible arrangements Key organizations secured as a piece of this analysis corporate. Bits of knowledge from this report would permit Marketing and the executives experts of organizations to settle on educated choice concerning their future item dispatches, 3D Bioprinting development, and promoting strategies. The Global 3D Bioprinting Market report takes into account different partners in this industry, including speculators, gadget makers, merchants and providers for 3D Bioprinting Market hardware, government associations, explore and counselling firms, new contestants, and budgetary investigators. Different system lattices utilized in breaking down the 3D Bioprinting Market would give partners essential contributions to settle on vital choices in like manner.

Price of 3D Bioprinting Market Report (Single User Licence): $ 4250

Purchase The 3D Bioprinting Market Report at: https://www.marketreportsworld.com/purchase/12343660

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Beverage Can Coatings in these regions, from 2018 to 2025 (forecast), covering

North America, Europe, China, Japan, Southeast Asia, India

About Market Reports World

Market is changing rapidly with the ongoing expansion of the industry. Advancement in the technology has provided today’s businesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies with a head start in planning and an edge over the competitors. Market Reports World is the credible source for gaining the market reports that will provide you with the lead your business needs.

Contact Info

Name: Ajay More

Phone: US +1 424 253 0807

Email: [email protected]

Related Posts:

  • No Related Posts

Global 3D Printing Healthcare Market 2025 report provides key aspects of the market, competitive …

key players: 3D Systems Corporations, Stratasys Ltd., SLM Solutions Group AG, EnvisionTEC, Arcam AB, Organovo Holdings, Inc., Oxford …

3D Printing Healthcare is a developing area of skill that travels how 3-D printing can be used to replace or support a present biological structure. Medical doctors have now begun using 3-D printers to produce medical devices. Examples of medical 3-D printing successes include the creation of plastic tracheal splints and limb prosthetics as well as titanium replacements for jaws and hips. 3-D printing signifies a shift in the medical manufacturing industry because the comparatively low cost and small size of printer’s potentials to make the technology widely nearby, letting doctors and investigators to create personalized devices for patients.

Global 3D Printing Healthcare Market was valued at $579.0 million in 2019, and is expected to garner $2,319.5 million by 2020, registering a CAGR of +30% during the forecast period 2019-2025.

The report classifies the 3D printing market in the healthcare industry by application, materials and geography. The healthcare applications market is segmented into medical, dental implants, prosthetics, and hearing & audibility aid among others. The materials market is segmented into metal & metal alloys, polymers, and ceramics among others.

For Sample Request:

https://www.healthcareintelligencemarkets.com/request_sample.php?id=4187

key players: 3D Systems Corporations, Stratasys Ltd., SLM Solutions Group AG, EnvisionTEC, Arcam AB, Organovo Holdings, Inc., Oxford Performance Materials, Inc., Materialise NV, Bio3D Technologies, and Cyfuse Medical K.K.

The growing focus on artistic healing techniques will be one of the major trends in the global 3D Printing Healthcare market during 2019-2025. The demand for beautifying dentistry has increased with individuals wanting to improve their appearances. The demand for allied and well-contoured teeth is driving the growth of the esthetic dentistry segment.

North America market dominates the global 3D Printing Healthcare market in terms of revenue influence as compared to that of markets in other regions. This is attributed to presence of well-developed dental substructure in the region. Europe accounts for second-largest revenue share contribution to the global 3D Printing Healthcare market, followed by markets in the Asia Pacific, Latin America, and the Middle East & Africa respectively.

Get up to 40% discount on this exclusive report:

https://www.healthcareintelligencemarkets.com/ask_for_discount.php?id=4187

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Key Highlights of The Clinical Immunoanalyzer Market:

The fundamental details related to Clinical Immunoanalyzer industry like the product definition, product segmentation, price, variety of applications, demand and supply statistics are covered in this report.

The comprehensive study of Clinical Immunoanalyzer market based on development opportunities, growth limiting factors and feasibility of investment will forecast the market growth.

The study of emerging Clinical Immunoanalyzer market segments and the existing market segments will help the readers in planning the business strategies.

For more enquiry:

https://www.healthcareintelligencemarkets.com/enquiry_before_buying.php?id=4187

Related Posts:

  • No Related Posts

Renaissance Technologies LLC Has $1.80 Million Stake in Organovo Holdings Inc (NASDAQ:ONVO)

Renaissance Technologies LLC boosted its position in Organovo Holdings Inc (NASDAQ:ONVO) by 25.4% in the 3rd quarter, according to the …

Organovo logoRenaissance Technologies LLC boosted its position in Organovo Holdings Inc (NASDAQ:ONVO) by 25.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,561,000 shares of the medical research company’s stock after purchasing an additional 316,400 shares during the period. Renaissance Technologies LLC owned approximately 1.35% of Organovo worth $1,795,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. raised its stake in shares of Organovo by 1.5% during the third quarter. BlackRock Inc. now owns 7,068,897 shares of the medical research company’s stock valued at $8,129,000 after acquiring an additional 102,486 shares in the last quarter. Virtu Financial LLC bought a new position in Organovo in the third quarter worth approximately $138,000. Finally, ARK Investment Management LLC raised its stake in Organovo by 20.8% in the third quarter. ARK Investment Management LLC now owns 17,951,107 shares of the medical research company’s stock worth $20,644,000 after buying an additional 3,090,669 shares in the last quarter. 36.15% of the stock is owned by institutional investors and hedge funds.

Several equities analysts have issued reports on the stock. Zacks Investment Research raised shares of Organovo from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a report on Thursday, October 11th. HC Wainwright initiated coverage on shares of Organovo in a report on Thursday, December 13th. They set a “buy” rating and a $2.50 price objective on the stock.

NASDAQ ONVO opened at $1.01 on Monday. The firm has a market cap of $117.05 million, a P/E ratio of -3.16 and a beta of 1.84. Organovo Holdings Inc has a 1 year low of $0.90 and a 1 year high of $2.09.

Organovo (NASDAQ:ONVO) last issued its quarterly earnings data on Thursday, November 8th. The medical research company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. The business had revenue of $0.94 million during the quarter, compared to the consensus estimate of $0.90 million. Organovo had a negative net margin of 732.47% and a negative return on equity of 65.73%. Equities analysts anticipate that Organovo Holdings Inc will post -0.25 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Renaissance Technologies LLC Has $1.80 Million Stake in Organovo Holdings Inc (NASDAQ:ONVO)” was first reported by Fairfield Current and is the sole property of of Fairfield Current. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.fairfieldcurrent.com/news/2019/02/04/renaissance-technologies-llc-boosts-stake-in-organovo-holdings-inc-onvo.html.

Organovo Profile

Organovo Holdings, Inc, a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.

Read More: What is the float in trading stocks?

Institutional Ownership by Quarter for Organovo (NASDAQ:ONVO)

Receive News & Ratings for Organovo Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Organovo and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts